Finerenone (chronic kidney disease associated with type 2 diabetes; stage 1 and 2 with albuminuria)

Subject:

• Active Substance: Finerenone
• Name: Kerendia®
• Therapeutic area: Chronic kidney disease
• Pharmaceutical company: Bayer Vital GmbH

Time table:

• Start: 01.03.2023
• Final decision by G-BA: 17.08.2023

Final decision:

• Hint for a non-quantifiable additional benefit